Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KIT positive |
| Therapy | Imatinib |
| Indication/Tumor Type | gastrointestinal stromal tumor |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KIT positive | gastrointestinal stromal tumor | sensitive | Imatinib | FDA approved | Actionable | In a Phase II trial that supported FDA approval, treatment with Gleevec (imatinib) resulted in an overall response rate of 38% (56/147) and a median duration of response of 13 weeks in patients with metastatic or unresectable KIT-positive GIST (PMID: 12374669). | 12374669 detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (12374669) | Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. | Full reference... |
| Gleevec (imatinib) FDA Drug Label | Full reference... |